Digest Network How does it work
Network
/
Society
No
Not verified

Novartis Pharma AG

What we write about

Advertising / Marketing / Media / CommunicatiManagementMedical Health WellnessPharmaceuticalsWant ads

109 Press releases

View all press releases
16/07/2026
Pharmaceuticals
Want ads
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
05/07/2026
Pharmaceuticals
Want ads
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
01/07/2026
Pharmaceuticals
Want ads
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
12/06/2026
Pharmaceuticals
Medical Health Wellness
Want ads
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
10/06/2026
Pharmaceuticals
Want ads
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
08/06/2026
Pharmaceuticals
Want ads
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
04/06/2026
Pharmaceuticals
Want ads
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
03/06/2026
Pharmaceuticals
Want ads
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
01/06/2026
Pharmaceuticals
Want ads
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0
31/05/2026
Pharmaceuticals
Want ads
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Source
Novartis Pharma AG
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0